GFM
RARE icon

GF Fund Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

GF Fund Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$68.3K Sell
2,045
-121
-6% -$3.01K ﹤0.01% 364
2026
Q1 		$45.4K Buy
2,166
+271
+14% +$6.1K ﹤0.01% 412
2025
Q4 		$43.6K Sell
1,895
-178
-9% -$5.85K ﹤0.01% 417
2025
Q3 		$62.4K Sell
2,073
-291
-12% -$8.73K ﹤0.01% 373
2025
Q2 		$86K Hold
2,364
– – ﹤0.01% 379
2025
Q1 		$85.6K Buy
2,364
+425
+22% +$17.7K ﹤0.01% 375
2024
Q4 		$81.6K Buy
+1,939
New +$96.2K ﹤0.01% 347

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

GF Fund Management's RARE Position: Q2 2026 in Review

GF Fund Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 5.6% in Q2 2026, selling an estimated $3.01K and leaving 2,045 shares worth $68.3K. The position accounts for ﹤0.01% of the portfolio, ranked #364.

GF Fund Management first reported a position in RARE in Q4 2024 and has held it in 7 quarters since. The position peaked at $86K in Q2 2025. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • GF Fund Management held 2,045 shares of Ultragenyx Pharmaceutical worth $68.3K as of Q2 2026.
  • GF Fund Management sold 121 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $3.01K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #364 holding.
  • GF Fund Management first reported a position in Ultragenyx Pharmaceutical in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Ultragenyx Pharmaceutical position peaked at $86K in Q2 2025.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.